CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $108,260,589 | +66.8% | 3,640,235 | +1.1% | 0.02% | +83.3% |
Q2 2023 | $64,902,849 | +11.2% | 3,601,712 | -0.9% | 0.01% | 0.0% |
Q1 2023 | $58,386,547 | +13.8% | 3,635,526 | +29.6% | 0.01% | +20.0% |
Q4 2022 | $51,322,076 | -0.8% | 2,804,485 | +6.5% | 0.01% | -9.1% |
Q3 2022 | $51,713,000 | +52.1% | 2,633,011 | +44.4% | 0.01% | +57.1% |
Q2 2022 | $34,010,000 | +50.5% | 1,823,598 | +77.2% | 0.01% | +75.0% |
Q1 2022 | $22,595,000 | -25.7% | 1,029,364 | -3.8% | 0.00% | -20.0% |
Q4 2021 | $30,407,000 | +58.2% | 1,070,272 | +17.2% | 0.01% | +66.7% |
Q3 2021 | $19,220,000 | +36.8% | 913,071 | +22.5% | 0.00% | +50.0% |
Q2 2021 | $14,051,000 | +66.5% | 745,387 | +35.0% | 0.00% | +100.0% |
Q1 2021 | $8,437,000 | +7.4% | 552,167 | -0.8% | 0.00% | 0.0% |
Q4 2020 | $7,854,000 | +14.5% | 556,635 | +27.2% | 0.00% | 0.0% |
Q3 2020 | $6,860,000 | +25.8% | 437,756 | +40.6% | 0.00% | 0.0% |
Q2 2020 | $5,453,000 | – | 311,281 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |